Presented on June 8, 2021
Patient-Derived Organoids & Assays for Cancer Research
With the increasing use of 3D cell structures for modeling tumors, organs, and tissue for translation research, there is a requirement for cancer models, assays and workflows to study patient-derived samples. In this webinar the speakers presented efforts of a successful collaboration of using our automated assay system (the Pu·MA System) with patient-derived organoids for developing an efficient workflow which was incorporated into a translational project which addressed therapeutics and drug resistance in triple negative breast cancer .
- Margarite Matossian, MD PhD (Tulane University Medical University)
Physician-Scientist in the group of Dr. Matthew Burow (Burow Lab website.
This study was funded by NIH & Krewe de Pink)
Patient-Derived Organoids: Translational Oncology research to Interrogate Therapeutic Responses & Drug Resistance
- Katya Nikolov, MD (Protein Fluidics, Inc.)
Senior Application Scientist
Automated Assays with Patient-Derived Organoids using the Pu·MA System
- The Pu·MA System can help prevent loss or damage during assay steps such as media exchange, supernatant sampling, or immunofluorescence staining.
- Patient-derived organoids were cultured from breast cancer patient samples for studying drug resistance
- To use these methods in a simple unified workflow
Protein Fluidics, Inc.
875 Cowan Road, Suite B,
Burlingame, CA 94010
+1 650 529 5080